Ghent, Belgium

Erik Hofman

This inventor holds 1 USPTO granted patent and 3 published patent applications and 1 EPO patent. Top assignee: Argenx Bv. Active years: 2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Erik Hofman. Retrieved from https://idiyas.com/inventor/erik-hofman

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 1 

% Patents Active = 100.0

 

Average Co-Inventor Count = 4.0

ph-index = 1


Company Filing History:


Years Active: 2024

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovative Journey of Erik Hofman

Introduction

Erik Hofman is a notable inventor based in Zwijnaarde, Ghent, Belgium. He is currently associated with Argenx Bv, a company known for its focus on innovative therapies. Although he holds no patents at this time, his contributions to the field of biotechnology are noteworthy.

Latest Patents

As of now, Erik Hofman has not registered any patents. This does not diminish his role in the innovative landscape, as his work at Argenx Bv contributes to the advancement of medical science.

Career Highlights

Erik Hofman has made significant strides in his career, particularly in the biotechnology sector. His work at Argenx Bv involves developing therapies that aim to address unmet medical needs. His expertise and dedication to innovation are evident in the projects he undertakes.

Collaborations

Due to space constraints, the collaborations section will be omitted.

Conclusion

Erik Hofman is an influential figure in the biotechnology field, contributing to innovative solutions at Argenx Bv. His journey reflects the importance of dedication and expertise in driving advancements in medical science.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…